Turn Therapeutics Inc. Common Stock
TTRXStock
$9.03
Market Cap$287.16M
P/E—
Div yield—
Beta0.01
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)106.02%
Price vs S&P 500 (4W)50.55%
VGM Score95.08
Market Capitalization$287.16M
Earnings Surprise History
Q4 250.01est. -0.04
Q1 26-0.03est. -0.03
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.13
4.13
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TTRXTurn Therapeutics Inc. Common Stock | — | — | A | $9.03 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Turn Therapeutics is a clinical-stage biotechnology company developing treatments for dermatology, wound care, and infectious diseases. The company's proprietary PermaFusion platform enhances drug stability and bioavailability, enabling lower doses and reduced side effects. Its lead programs target moderate to severe eczema and onychomycosis.